Health Policy and Management (보건행정학회지)

Korean Academy of Health Policy and Management (한국보건행정학회)
권호 표지
DOI QR코드

DOI QR Code

Review of Economic Evaluation Studies for Drug Reimbursement Decision

의약품 보험급여 결정을 위한 경제성평가 연구의 평가

  • Choi Sang-Eun (Health Insurance Review Agency) ;
  • Sullivan Sean D. (University of Washington)
  • 최상은 (건강보험심사평가원 조사연구실) ;
  • Published : 2005.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Legislation on pharmaceutical reimbursement decision using economic evaluation results was made in Korea in fm, but has yet to be fully implemented. We evaluated the quality of Korean economic evaluation studies of pharmaceuticals to understand gaps between legislation and implementation. From this evaluation, we propose policy options that might strengthen the research Infrastructure In order to support such studies. We reviewed 23 published studies for drugs conducted between 1996 and 2004. Evaluation criteria included methodological characteristics, healthcare system characteristics, population characteristics, and applicability of results. Large variation in study quality was observed, particularly with study design, outcome data, treatment patterns and interpretation. Korean clinical data used was mostly from observational studies of 1-2 hospitals. Foreign data was extracted from clinical trials that did not Include Asian population and their selection criterion was not clarified. With respect to treatment patterns, medical records and hospital bills were used without adjustment regarding area, hospital type, and others. And next frequent situation relied on expert opinion from academic physicians in specialty practice. preference measures, when used, were not elicited from the Korean population. $78.3\%$ of studies did not clarify the funding source. If the Korean economic evaluation policy is to provide meaningful data for decision makers, the quality of cost-effectiveness studies will need to improve dramatically. This may involve access to or creation of better data, more diverse funding, unproved training of researchers and evaluators, and partnerships with technology manufacturers.

Keywords

References

  1. 이건세, Brouwer WBF, 이상일, 구혜원. 보건의료 경제성평가 방법론 고찰-연구설계와 비용추정을 중심으로. 보건행정학회지 2004; 14(2):58-77
  2. 이의경, 배은영, 이태진, 최용준, 박은자, 김동숙. 보험의약품의 급여관리제도 개선방안. 한국보건사회연구원.보건복지부 2003
  3. 최용준, 이태진, 이의경, 김윤. 우리나라 의약품 비용효과분석 연구의 현황. 보건경제연구 2003; 9(1): 59-78
  4. Anis AH and Gagnon Y. Using Economic Evaluations to Make Formulary Coverage Decisions. So much for Guidelines. Pharmacoeconomics. 2000 Jul; 18(1): 55-62 https://doi.org/10.2165/00019053-200018010-00006
  5. Baladi JF, MenonD, Otten N. Use of Economic Evaluation Guidelines: 2 years' Experience in Canada. Health Econonomics. 1998; 7:221-227 https://doi.org/10.1002/(SICI)1099-1050(199805)7:3<221::AID-HEC341>3.0.CO;2-N
  6. Briggs A and Fenn P. Trying to do Better than Average: A coomentary on 'Statstical Inference for CostEffectiveness Ratios'. Health Economics 1997; 6:491-495 https://doi.org/10.1002/(SICI)1099-1050(199709)6:5<491::AID-HEC293>3.0.CO;2-R
  7. Canadian Coordinating Office for Health Technology Assessment, Guidelines for Authors of CCOHTA Health Technology Assessment Reports, June 2001 Revised May 2003. Available from URL: https://www.ccohta.ca/entry_e.html
  8. Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and Validation of a Grading System for the Quality of Cost-effectiveness Studies. Medical Care 2003; 41(1):32-44 https://doi.org/10.1097/00005650-200301000-00007
  9. Drummond M and McGuire A. Economic Evaluation in Health Care: Merging theory with practice. Oxford University Press; 2001. pp. 256-276
  10. Drummond MF and Jefferson TO. Guidelines for Authors and Peer Reviewers of Economic Submissions to the BMJ. BMJ 1911; 313:275-283
  11. Drummond MF, O'Brien B, Stoddart GL, and Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, $2^{nd}$ Ed. Oxford Medical Publications; 1997. pp. 39-41
  12. Drummond MF. A Reappraisal of Economic Evaluation of Pharmaceuticals: Science or Marketing? Pharmacoeconomics 1998 Jul; 14(1); 1-9
  13. Drummond MF. The Use of Health Economic Information by Reimbursement Authorities. Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii60-3 https://doi.org/10.1093/oxfordjournals.rheumatology.a005753
  14. Enstrom A, Jacob J, Lundin D, Odeberg S, Ramsberg J. Examinging the Quality of Health Economic Analyses Submitted to the Pharmaceutical Benefits Board in Sweden. ISPOR $10^{th}$ Annual Meeting Poster Presentation. 2005
  15. George B, Harris A, Mitchell A Costeffectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19(11):1103-9 https://doi.org/10.2165/00019053-200119110-00004
  16. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press 1996
  17. Helmgren J. Berggren F, Anderson F. Health Economic Guidelines -Similarities, Differences and Some Implications. Value in Health 2001; 4(3); 224-250
  18. Hill SR, Mitchell AS, Herny DA. Problems With the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000 April; 283(16); 2116-2121 https://doi.org/10.1001/jama.283.16.2116
  19. National Institute for Clinical Excellence. Guide to the Method of Technology Appraisal. April 2004. Available from URL: http://www.nice.org.uk/page.aspx?o=201971
  20. Ofman JJ, Sullivan SD, Neuman PJ, Choiu CF, Hennig JM, Wade SW, Hay JW. Examining the Value and Quality of Health Economic Analysis: Implications of Utilizing the QHES, JMCP. 2003;9(1): 53-61
  21. Sculpher M, Fenwick E, Claxton K, Assessing Quality in Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics 2000 May; 17(5); 461-477 https://doi.org/10.2165/00019053-200017050-00005
  22. Tarn TYH, Smith MD, Pharmacoeconomic Guidelines Around the World, ISPOR newsletter CONNECTIONS 2004; 10(4)
  23. Welte R, Feenstra T, Jager H and Leid R, A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries, Pharmacoeconomics 2004; 22(13): 857-876 https://doi.org/10.2165/00019053-200422130-00004
  24. http:;/www.ispor.org/PEguidelines/index.asp

Cited by

  1. Current State and Challenges of Pharmacoeconomic Evaluation in Korea vol.41, pp.2, 2008, https://doi.org/10.3961/jpmph.2008.41.2.74